CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo immune programming. The company's proprietary mRNA-LNP platform directly engineers T cells, NK cells, and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies. CREATE is advancing a pipeline of in vivo CAR therapies across autoimmune diseases and cancer.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
05/14/26	$122,000,000	Series B	Alexandria Venture Investments ARCH Venture Partners Hatteras Venture Partners Newpath Partners	undisclosed